Hebrew Site 

12/31/2003- Pharmos Ltd. Will Join Teva, AGis, Harlan and Compugen in the Pharma-Logic Consortium 12/19/2003- Pharmos Corporation Completes $27 Million Equity Offering 12/16/2003- Pharmos Corporation Announces Pricing of Public Offering 12/10/2003- Pharmos Corporation to Present at the Harris Nesbitt Gerard Focus on Healthcare Conference 12/02/2003- Pharmos to Offer Shares of Its Common Stock to Public 11/12/2003- Pharmos Reports Progress in CB2-selective Program at Society for Neuroscience Annual Meeting 11/05/2003- Pharmos Corporation Reports 2003 Third Quarter Results Phase III Brain Injury Study Advances with 750 Patients Enrolled 11/05/2003- FDA Accepts Bausch & Lomb New Drug Application for Ophthalmic Anti-inflammatory/Antibiotic Combination Product 10/22/2003- Pharmos to Delist from Nasdaq Europe Effective November 6, 2003 10/15/2003- Pharmos Corporation to Present at the Rodman & Renshaw Techvest Healthcare Conference 09/30/2003- Pharmos Receives FDA Fast Track Designation for Dexanabinol 09/30/2003- Pharmos Completes $21 Million Convertible Debt Transaction with Institutional Investors 09/23/2003- Pharmos Corporation to Present at Friedland Capital's Biotech, Medical and Healthcare Conference Featuring Companies Covered by J. M. Dutton & Associates 08/07/2003- Pharmos Corporation Reports 2003 Second Quarter Results - Momentum Builds in U.S. Clinical Operations and Cognitive Impairment Trial 07/01/2003- Pharmos Initiates US Enrollment in Phase III Study of Dexanabinol For Traumatic Brain Injury 06/10/2003- Pharmos Corporation Receives Notice of Allowance for U.S. Patent 06/02/2003- Pharmos Raises $8 Million in Private Equity Transaction With Institutional Investors 05/20/2003- Pharmos Receives 2003 Grant from Israel Office of Chief Scientist 05/07/2003- Pharmos Corporation Reports 2003 First Quarter Resuls (PDF file) 04/08/2003- Pharmos Dosing Patients in Second Brain Protection Indication for Dexanabinol 03/07/2003- Pharmos Corporation Reports 2002 Results Cost Containment Program Tightens 2003 Expenses (PDF file) 03/04/2003- Pharmos Sells $4.3 Million in Common Stock; Redeems Balance of Convertible Debentures 02/26/2003- Pharmos Corporation to Present at the BIO CEO & Investor Conference 02/18/2003- Pharmos Expands International Head Trauma Study of Dexanabinol into the U.S.

More News:

<< 2004 News >>     << 2002 News >>     << 2001 News >>